Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > G12D/G12V KRAS mutation in PC & CRC patients respond to Pela

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Oct 08, 2023 12:42pm

119 Views

Post# 35675213

RE:RE:RE:G12D/G12V KRAS mutation in PC & CRC patients respond to Pela

It's unbelievable the attention MRTX gets from BP, analysts and all, and how little Oncy receives when we have so much going for us. Not that the following means much, but SWS has a fair value of $331 attributable to MRTX and Oncy $44. The investment world needs to wake up to Oncy.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing